ROMVIMZA Trademark

Trademark Overview


On Wednesday, October 25, 2023, a trademark application was filed for ROMVIMZA with the United States Patent and Trademark Office. The USPTO has given the ROMVIMZA trademark a serial number of 98238958. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, July 23, 2024. This trademark is owned by Deciphera Pharmaceuticals, LLC. The ROMVIMZA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical and biological preparations for treating tenosynovial giant cell tumor (TGCT), giant cell tumor of the tendon sheath (GCT-TS), and pigmented villonodular synovitis (PVNS); Pharmaceutical and biological preparations for use in orthopedics, rheumatology, oncology, neurology, immunology, and hematology; Pharmaceutical and biological preparations for preventing, diagnosing, treating and managing diseases, disorders, and conditions affecting the musculoskeletal system, central nervous system, immune system, and blood; Pharmaceutical and biological preparations for treating tumors, sarcomas, tenosynovial giant cell tumors, graft versus host disease (GVHD), Parkinson's disease, Alzheimer's disease, and Amyotrophic Lateral Sclerosis (ALS); Therapeutic agents, namely, kinase inhibitors
romvimza

General Information


Serial Number98238958
Word MarkROMVIMZA
Filing DateWednesday, October 25, 2023
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, July 23, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 28, 2024

Trademark Statements


Goods and ServicesPharmaceutical and biological preparations for treating tenosynovial giant cell tumor (TGCT), giant cell tumor of the tendon sheath (GCT-TS), and pigmented villonodular synovitis (PVNS); Pharmaceutical and biological preparations for use in orthopedics, rheumatology, oncology, neurology, immunology, and hematology; Pharmaceutical and biological preparations for preventing, diagnosing, treating and managing diseases, disorders, and conditions affecting the musculoskeletal system, central nervous system, immune system, and blood; Pharmaceutical and biological preparations for treating tumors, sarcomas, tenosynovial giant cell tumors, graft versus host disease (GVHD), Parkinson's disease, Alzheimer's disease, and Amyotrophic Lateral Sclerosis (ALS); Therapeutic agents, namely, kinase inhibitors

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, October 31, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameDeciphera Pharmaceuticals, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressWaltham, MA 02451

Party NameDeciphera Pharmaceuticals, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressWaltham, MA 02451

Trademark Events


Event DateEvent Description
Saturday, October 28, 2023NEW APPLICATION ENTERED
Tuesday, October 31, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, January 12, 2024ASSIGNED TO EXAMINER
Saturday, January 13, 2024NON-FINAL ACTION WRITTEN
Saturday, January 13, 2024NON-FINAL ACTION E-MAILED
Saturday, January 13, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, April 12, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, April 12, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, April 12, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, April 20, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 8, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 28, 2024PUBLISHED FOR OPPOSITION
Tuesday, May 28, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 23, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, January 8, 2025SOU TEAS EXTENSION RECEIVED